Login
Need to Register?   Forgot Password?
2013 ACC/AHA Cholesterol Guidelines for ASCVD Risk Reduction in Adults
Update to ATP III cholesterol guidelines
Source: Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2013. doi:10:1016/j.jacc.2013.11.002. Available here.
Refer to source document for full recommendations, including class of recommendation and level of evidence.
Jump to a section or click the arrow at the bottom right of each section to advance

Statin Benefit Groups for ASCVD Risk Reduction
Statin Benefit Group 1: Clinical ASCVD—Secondary Prevention
Statin Benefit Group 2: Primary
LDL-C ≥190—Primary Prevention

Statin Benefit Group 3: Age 40-75 With Diabetes & LDL-C 70-189—Primary Prevention
Statin Benefit Group 4: Age 40-75,
LDL-C 70-189, estimated 10-yr ASCVD risk ≥7.5%—Primary Prevention

Abandoning LDL-C, Non–HDL-C Targets

Primary Prevention for Individuals With Unclear Risk Assessment
10-Year ASCVD Risk Assessment
Statin Safety Recommendations
Monitoring & Optimizing Statin Therapy
Safety Recommendations for Nonstatin Drugs
Heart Failure & Hemodialysis

Statin Benefit Groups for ASCVD Risk Reduction

Recommendations

High- or moderate-intensity statin therapy for all individuals at increased risk for ASCVD who are likely to benefit from risk reduction

Individuals stratified into 4 statin benefit groups:

  1. Clinical ASCVD—secondary prevention
  2. Primary LDL-C ≥190 mg/dL—primary prevention
  3. Age 40-75 with diabetes & LDL-C 70-189 mg/dL—primary prevention
  4. Age 40-75 with LDL-C 70-189 mg/dL and estimated 10-yr ASCVD risk ≥7.5%>
    —primary prevention

ASCVD risk reduction benefit outweighs the risk for adverse effects of statin therapy in these individuals

Lifestyle modification is the cornerstone before and during cholesterol-lowering therapy

Click on slide thumbnail to view larger. All slides available for download in the slide library.

ACC/AHA 2013 Cholesterol Guidelines: ASCVD Risk Reduction is Goal

ACC/AHA 2013 Cholesterol Guidelines: Statin Benefit Groups for ASCVD Prevention
   
 
ACC/AHA 2013 Cholesterol Guidelines: High- and Moderate-Intensity Statin Therapy  

 

   
Next

ASCVD=atherosclerotic cardiovascular disease

The pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual package inserts for use outside of the United States.

February 2014

This content was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.

Back to Clinical Guidelines

Case Study: Clinical Application of the ACC/AHA Cholesterol Guidelines